Ishita Drugs & Industries Limited (524400) Fair Value & Analysis
Other · IN · Market cap ₹64.3M
Fair value as of: Jul 4, 2026
From 22 valuation models · updated today
Share price −6.3% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹67.60 – ₹84.64 · fair‑value band ₹33.19 – ₹55.32 · the ₹73.10 price screens above the ₹44.26 fair value. As of Jul 4, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Ishita Drugs & Industries Limited (524400) currently trades at ₹73.10, while our model-based Fair Value estimate is ₹44.26 — implying the stock looks roughly 39.5% overvalued today. We read business quality at 56/100 (solid quality), in the Other sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Ishita Drugs & Industries Limited generated revenue of ₹135M at a net margin of 4.0%. Revenue grew 6.2% year over year. It earns a return on equity of 7.8%. Net debt stands at ₹33.3M. Fundamentals as of Jul 4, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 4, 2026. TTM = trailing twelve months.
About the company
Ishita Drugs & Industries Limited manufactures and sells active pharma ingredients and drug intermediates in India. It offers active pharma ingredients, such as sulfa drugs/sulfonamides, vitamins, fluoro quinolones, antibiotics, anthelmintics, iodides and citrates, food additives/excipients, and others; fine chemicals; and drug intermediaries, as well as finished dosage forms. The company also provides contract manufacturing services for various drug intermediates, fine chemicals, or specialty chemicals. It serves regulatory authorities and pharmaceutical companies. The company exports its products to approximately 25 countries. Ishita Drugs & Industries Limited was incorporated in 1992 and is based in Ahmedabad, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Ishita Drugs & Industries Limited reported revenue of ₹147M in FY2026 versus ₹141M in FY2022, a compound +1.0%/yr. Reported net income was ₹7.8M in FY2026, compounding −0.8%/yr from FY2022.
Is 524400 fairly valued? → Check now
Similar stocks
6 more Other stocks, each showing price versus our Fair Value estimate (as of Jul 4, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| There MOH | €521.90 | €209.16 | -60% |
| Sony Corporation SON1 | €17.58 | €39.38 | +124% |
| Federal Home Loan Mortgage Corporation FREJO | $16.84 | $28.75 | +71% |
| 533278 533278 | ₹438.60 | ₹720.31 | +64% |
| Nestl?? India Limited 500790 | ₹1,459 | ₹279.60 | -81% |
| 540376 540376 | ₹3,993 | ₹1,806 | -55% |
Explore undervalued stocks
Frequently asked questions
Is Ishita Drugs & Industries Limited (524400) undervalued?
What is the fair value of 524400?
What is the quality score of 524400?
What is the revenue of Ishita Drugs & Industries Limited (524400)?
What is the net profit margin of 524400?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.